Paeoniflorin as a Promising Therapeutic Candidate in Intestinal Diseases: Experimental Evidence, Mechanistic Insights, and Translational Perspectives
Drug Design, Development and Therapy · 2026-06 · Volume 20 · 1-21
DOI: 10.2147/dddt.s617375 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Design, Development and Therapy, 2026-06. Verfasst von Congcong Chang und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China. Hauptthemen laut MEDLINE: Monoterpenes, Glucosides, Intestinal Diseases, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Intestinal diseases, including inflammatory bowel disease, functional bowel disorders, stress-related enteropathy, colorectal cancer, and colitis-associated colorectal cancer, share overlapping pathological processes such as epithelial barrier disruption, immune dysregulation, microbiota imbalance, oxidative stress, and inflammation-driven tissue injury. Paeoniflorin, a major monoterpene glycoside derived from Paeonia species, has attracted increasing attention because of its anti-inflammatory, antioxidant, immunomodulatory, anti-apoptotic, and barrier-protective properties. This review summarizes experimental evidence and mechanistic findings regarding the therapeutic potential of paeoniflorin in intestinal diseases. Current preclinical studies suggest that paeoniflorin can alleviate colitis, improve epithelial barrier integrity, promote mucosal repair, modulate microbiota-metabolite interactions, reduce visceral hypersensitivity, and suppress inflammation-associated colorectal tumorigenesis. Mechanistically, these effects involve coordinated regulation of inflammatory signaling, immune-cell balance, epithelial regeneration, gut-brain axis-related pathways, and oncogenic inflammatory cascades. Recent advances in colon-targeted delivery, pharmacokinetic modulation, compatibility-dependent exposure, and derivative development further support its translational potential. However, existing evidence remains largely based on in vitro and animal studies, with limited clinical data, heterogeneous models and dosing regimens, insufficient PK/PD validation, and unresolved druggability challenges. Future research should integrate mechanistic validation, optimized delivery systems, exposure-response evaluation, and clinically relevant disease stratification to support its progression from a bioactive natural compound to a viable intestinal therapeutic candidate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
- First School of Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, People's Republic of China.
Zitieren
APA
Chang, C., Xue, J., Xu, Z., & Hou, G. (2026). Paeoniflorin as a Promising Therapeutic Candidate in Intestinal Diseases: Experimental Evidence, Mechanistic Insights, and Translational Perspectives. Drug Design, Development and Therapy, Volume 20, 1-21. https://doi.org/10.2147/dddt.s617375
Vancouver
Chang C, Xue J, Xu Z, Hou G. Paeoniflorin as a Promising Therapeutic Candidate in Intestinal Diseases: Experimental Evidence, Mechanistic Insights, and Translational Perspectives. Drug Design, Development and Therapy. 2026;Volume 20:1-21. doi:10.2147/dddt.s617375
BibTeX
@article{Chang2026,
author = {Chang, Congcong and Xue, Jing and Xu, Ziyou and Hou, Guanqun},
title = {Paeoniflorin as a Promising Therapeutic Candidate in Intestinal Diseases: Experimental Evidence, Mechanistic Insights, and Translational Perspectives},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--21},
doi = {10.2147/dddt.s617375}
}
EUVIMED